Change Password!
Reset Password!
Lebrikizuma proved to have favourable outcomes for tough-to-treat atopic dermatitis, improving outcomes and quality of life.
In the realm of dermatology, atopic dermatitis (AD) presents as a troubling skin condition due to its multifaceted nature. Seeking to address this, a recent study investigated into the efficacy of Lebrikizumab, a promising monotherapy.
This examination, circling the ADvocate 1 and ADvocate 2 trials, focused on Lebrikizumab's impact on adults with AD with moderate-to-severe intensity. Over 16 weeks, Lebrikizumab at 250 mg dosage, was administered every two weeks and compared against a placebo.
Significant improvements were witnessed across various parameters. Notably, patients treated with Lebrikizumab exhibited a rapid and consistent reduction in AD severity across all body regions, including challenging areas like the head and neck.
The evaluation, conducted via the Eczema Area and Severity Index (EASI), exposed notable progress. By week 16, Lebrikizumab recipients demonstrated substantial enhancements in EASI scores, with improvements evident as early as week 2. In both trials, patients had significant symptom relief (erythema, oedema/papulation, excoriation [skin-picking] and lichenification [hard and thickened skin]), with improvements observed across all body regions.
Dermatology and Therapy
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Eric L. Simpson et al.
Comments (0)